FAIRFIELD, N.J., May 1 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today announced that Daniel Glassman, President and CEO, will participate in the UBS Global Generic and Specialty Pharmaceuticals Conference at the Grand Hyatt New York. Mr. Glassman is scheduled to present on Tuesday May 8, 2007, at 8:30 AM (EDT).
The presentation will be webcast live and can be accessed by visiting http://www.bradpharm.com and clicking on Calendar of Events.
Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com.
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley’s success is based upon its core strengths in marketing and sales which enables the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley’s marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OBGYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Important announcement:
Bradley Pharmaceuticals will present at the Robbins Emerging Opportunities Investment Conference, to be held at The University Club in New York, NY, May 24, 2007.
Bradley Pharmaceuticals will present at the Banc of America Securities Health Care Conference 2007, at 9:20 a.m., to be held at The Four Seasons Hotel in Las Vegas, Nevada, May 30 - June 1, 2007.
Bradley Pharmaceuticals will present at the FTN Midwest Securities Health Care Conference 2007, to be held at the Four Seasons Hotel in New York, NY, June 5, 2007.
Safe Harbor for Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as Bradley’s plans to in-license, develop and launch new and enhanced products with long-term intellectual property protection or other significant barriers to market entry, predictions of financial performance, market acceptance of Bradley’s products, and the achievement of initiatives to enhance corporate governance and long-term shareholder value. Forward-looking statements are based on Bradley’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Bradley’s control. These risks and uncertainties include Bradley’s ability to: launch VEREGEN(TM) and ELESTRIN(TM) during 2007; predict the safety and efficacy of these products in a commercial setting; maintain adequate inventory of levels; favorably resolve the pending SEC informal inquiry; maintain or increase sales of its products; or effectively react to other risks and uncertainties described from time to time in Bradley’s SEC filings. Further, Bradley cannot accurately predict the impact on its business of the approval, introduction, or expansion by competitors of generic or therapeutically equivalent or comparable versions of Bradley’s products or of any other competing products. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Bradley Pharmaceuticals, Inc.
CONTACT: Cecelia C. Heer, Investor Relations of Bradley Pharmaceuticals,Inc., +1-973-882-1505, ext. 252
Web site: http://www.bradpharm.com/
